Genmab — November 2019
-
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma. https://clinicaltrials.gov/ct2/show/NCT04151667?term=daratumumab&draw=1&rank=39
-
Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma. https://clinicaltrials.gov/ct2/show/NCT04150692?term=daratumumab&draw=1&rank=23
-
Plesner/Abildgaard får afslag på off-label venetoclax i HR MM https://haematologisktidsskrift.dk/sygdomme/myeloma/648-myelomatoseeksperter-far-afslag-pa-off-label-behandling-med-god-effekt.html
-
Jeps...Og pladsen bliver vist hele tiden større i dag.
-
Der ligger vist ikke et rebound i kortene i dag.
-
?
-
Den slags er noget nyt.
-
HALO skærer virksomheden til ved at fyre over halvdelen af medarbejderne samt fokusere på det stof der bruges i dara sc. Mener det kan blive en rigtig god langsigtet investering med tanke på at dara sc kaster 5% royalty af sig. Herudover mange andre tilsvarende aftaler. Sorry for at benytte Genmab chatten - vi kunne tage den i biotech chatten.
-
Tragisk..David Eatwell mistede sin hustru i sommers. Derfor logisk, at han trækker sig for af hensyn til børnene.https://borsen.dk/nyheder/virksomheder/artikel/1/390639/genmabs_jan_van_de_winkel_familiedrama_bag_finansdirektoers_exit.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind